The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars.
The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, serves as an online resource that brings together the worlds of clinical, business, regulatory, policy, and economic outcomes of biosimilars.
The introduction of biosimilars to the United States provides great promise, as they are expected to bring down the price of medications, but also challenges. Biosimilars face stringent regulatory requirements, continued education of patients and physicians, and ongoing litigation issues.
In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars. For more insight into the world of biosimilar therapies, visit centerforbiosimilars.com.
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024
January 14th 2024Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen